Literature DB >> 17327340

Progressive loss of beta-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes.

Miriam Cnop1, Josep Vidal, Rebecca L Hull, Kristina M Utzschneider, Darcy B Carr, Todd Schraw, Philipp E Scherer, Edward J Boyko, Wilfred Y Fujimoto, Steven E Kahn.   

Abstract

OBJECTIVE: The relative roles of insulin resistance and beta-cell dysfunction in the pathogenesis of impaired glucose tolerance (IGT) and type 2 diabetes are debated. First-degree relatives of individuals with type 2 diabetes are at increased risk of developing hyperglycemia. RESEARCH DESIGN AND METHODS: We evaluated the evolution of insulin sensitivity, beta-cell function, glucose effectiveness, and glucose tolerance over 7 years in 33 nondiabetic, first-degree relatives of type 2 diabetic individuals using frequently sampled tolbutamide-modified intravenous and oral glucose tolerance tests.
RESULTS: Subjects gained weight, and their waist circumference increased (P < 0.05). Insulin sensitivity, the acute insulin response to glucose, and glucose effectiveness did not change significantly. However, when we accounted for the modulating effect of insulin sensitivity on insulin release, beta-cell function determined as the disposition index decreased by 22% (P < 0.05). This decrease was associated with declines in intravenous and oral glucose tolerance (P < 0.05 and P < 0.001, respectively). Of the subjects with normal glucose tolerance at the first assessment, we compared those who progressed to IGT with those who did not. The disposition index was 50% lower in the progressors than in the nonprogressors at follow-up (P < 0.05).
CONCLUSIONS: The decline in glucose tolerance over time in first-degree relatives of type 2 diabetic individuals is strongly related to the loss of beta-cell function. Thus, early interventions to slow the decline in beta-cell function should be considered in high-risk individuals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17327340     DOI: 10.2337/dc06-1834

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  69 in total

1.  Exogenous insulin enhances glucose-stimulated insulin response in healthy humans independent of changes in free fatty acids.

Authors:  Ximena Lopez; Aaron Cypess; Raquel Manning; Sheila O'Shea; Rohit N Kulkarni; Allison B Goldfine
Journal:  J Clin Endocrinol Metab       Date:  2011-09-28       Impact factor: 5.958

Review 2.  Dynamics of insulin secretion and the clinical implications for obesity and diabetes.

Authors:  Susumu Seino; Tadao Shibasaki; Kohtaro Minami
Journal:  J Clin Invest       Date:  2011-06-01       Impact factor: 14.808

3.  Regression to Normal Glucose Regulation in American Indians and Alaska Natives of a Diabetes Prevention Program.

Authors:  Katherine A Pratte; Ann Johnson; Janette Beals; Ann Bullock; Spero M Manson; Luohua Jiang
Journal:  Diabetes Care       Date:  2019-06-08       Impact factor: 19.112

4.  Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study.

Authors:  R A DeFronzo; M A Banerji; G A Bray; T A Buchanan; S Clement; R R Henry; A E Kitabchi; S Mudaliar; N Musi; R Ratner; P Reaven; D C Schwenke; F D Stentz; D Tripathy
Journal:  Diabetologia       Date:  2009-12-10       Impact factor: 10.122

5.  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study.

Authors:  Adam G Tabák; Markus Jokela; Tasnime N Akbaraly; Eric J Brunner; Mika Kivimäki; Daniel R Witte
Journal:  Lancet       Date:  2009-06-08       Impact factor: 79.321

6.  Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARgamma pathway as a therapeutic target in Friedreich's ataxia.

Authors:  Giovanni Coppola; Daniele Marmolino; Daning Lu; Qing Wang; Miriam Cnop; Myriam Rai; Fabio Acquaviva; Sergio Cocozza; Massimo Pandolfo; Daniel H Geschwind
Journal:  Hum Mol Genet       Date:  2009-04-17       Impact factor: 6.150

7.  Effects of exercise training intensity on pancreatic beta-cell function.

Authors:  Cris A Slentz; Charles J Tanner; Lori A Bateman; Michael T Durheim; Kim M Huffman; Joseph A Houmard; William E Kraus
Journal:  Diabetes Care       Date:  2009-07-10       Impact factor: 19.112

8.  Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB.

Authors:  Daniel A Cunha; Laurence Ladrière; Fernanda Ortis; Mariana Igoillo-Esteve; Esteban N Gurzov; Roberto Lupi; Piero Marchetti; Décio L Eizirik; Miriam Cnop
Journal:  Diabetes       Date:  2009-08-31       Impact factor: 9.461

Review 9.  Goals of treatment for type 2 diabetes: beta-cell preservation for glycemic control.

Authors:  Piero Marchetti; Roberto Lupi; Silvia Del Guerra; Marco Bugliani; Valentina D'Aleo; Margherita Occhipinti; Ugo Boggi; Lorella Marselli; Matilde Masini
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

10.  Defining and characterizing the progression of type 2 diabetes.

Authors:  Vivian A Fonseca
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.